ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "diagnosis"

  • Abstract Number: 1954 • 2015 ACR/ARHP Annual Meeting

    How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis?

    Cristina Ponte1,2, Sophie Vaggers1, Jan Sznajd1, Lorraine O'Neill1, Jennifer Piper3, Jessica Gunn1, Kulveer Mankia1 and Raashid Luqmani1, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

    Background/Purpose: Giant cell arteritis (GCA), the most common primary vasculitis, can cause irreversible blindness in 20-30% of untreated cases, but glucocorticoid therapy leads to significant…
  • Abstract Number: 1963 • 2015 ACR/ARHP Annual Meeting

    Specialty of Provider Referring for Temporal Artery Biopsy Affects the Likelihood of Giant Cell Arteritis (GCA) Diagnosis

    Lindsay Lally1 and Robert F. Spiera2, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Rheumatology, HSS, New York, NY

    Background/Purpose: Presenting signs/symptoms of GCA can be nonspecific and patients can initially present to a spectrum of clinical specialties.  While temporal artery biopsy (TAB) is…
  • Abstract Number: 2160 • 2015 ACR/ARHP Annual Meeting

    The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis: A Diagnostic Accuracy and Cost-Effectiveness Study

    Raashid Luqmani1, Ellen Lee2, Surjeet Singh3, Michael Gillett2, Wolfgang A. Schmidt4, Mike Bradburn2, Bhaskar Dasgupta5,6, Andreas P Diamantopoulos7, Wulf Forrester-Barker8, William Hamilton9, Shauna Masters10, Brendan McDonald11, Eugene McNally8, Colin T. Pease12, Jennifer Piper8, John Salmon13, Allan Wailoo2, Konrad Wolfe14, Andrew Hutchings15 and TABUL Study group, 1Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, 31Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 4Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 5Rheumatology, Southend University Hospital, Essex, United Kingdom, 6Southend University Hospital, Essex, United Kingdom, 7Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 8Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 9Primary Care, University of Exeter, Exeter, United Kingdom, 10Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, 11Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 12Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 13Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 14Department of Pathology, Southend University Hospital, Essex, United Kingdom, 15Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom

    Background/Purpose: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis which if untreated can lead to permanent sight loss. It is…
  • Abstract Number: 2298 • 2015 ACR/ARHP Annual Meeting

    Misdiagnosis of Fibromyalgia (FM) As Axial Spondylarthritis (SpA): Lessons from Analysis of 26 Cases

    Dongfeng Liang, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China

    Background/Purpose: Both patients with fibromyalgia (FM) and with axial spondyloarthritis (SpA) are suffering from pain.  The patients with axial SpA are mainly manifested as inflammatory…
  • Abstract Number: 2441 • 2015 ACR/ARHP Annual Meeting

    Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis

    Alan M. Rosenberg1, Walter Maksymowych2, Yuan Gui3 and Anthony Marotta3, 1Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Augurex Life Sciences Corp., Vancouver, BC, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a collective term used to denote clinically discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis, Polyarthritis, Psoriatic arthritis, Systemic arthritis…
  • Abstract Number: 2443 • 2015 ACR/ARHP Annual Meeting

    Pediatric Tele-Rheumatology: A Pilot Project to Assess Accuracy of Physical Examination Findings and Diagnostic Concordance at a Distance

    Michael Henrickson1, Jody Raugh2, Kelsey Hofacer3 and Adam Furnier4, 1Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Occupational and Physical Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Center for Telehealth, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Quality Improvement Systems, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Telemedicine (TM) offers a strategic means of extending limited clinical pediatric rheumatology (PR) workforce capacity to improve access to care for patients in remote…
  • Abstract Number: 2453 • 2015 ACR/ARHP Annual Meeting

    Evidence-Based Decision Support for Pediatric Rheumatology Reduces Diagnostic Errors, with the Potential to Reduce Capacity Shortage

    Balu Athreya1, Mary Beth Son2, Jonathan S. Hausmann3, Elizabeth Ang4, David Zurakowski5, Michael Segal6 and Robert Sundel7, 1duPont Hospital for Children/Thomas Jefferson University, Wilmington, DE, 2Division of Immunology, Children's Hospital Boston, Boston, MA, 3Rheumatology, Children's Hospital Boston, Boston, MA, 4Paediatrics, University Children's Medical Institute, NUH, Singapore, Singapore, 5Departments of Anesthesia and Surgery, Boston Children’s Hospital, Boston, MA, 6SimulConsult, Chestnut Hill, MA, 7Immunology, Childrens Hospital, Boston, MA

    Background/Purpose: This projects seeks to respond to the critical shortage of pediatric rheumatologists encapsulating the diagnostic information of the field in an advanced diagnostic decision…
  • Abstract Number: 2585 • 2015 ACR/ARHP Annual Meeting

    Serum 14-3-3η Is an RA Specific Mechanistic Marker

    Bidisha Dasgupta1, Yauheniya Cherkas1, Sarah Lamberth1, Karen Hayden1, Carrie Brodmerkel1, Anthony Marotta2 and Mark Curran1, 1Janssen Research & Development, LLC., Spring House, PA, 2Augurex Life Sciences Corp., Vancouver, BC, Canada

    Background/Purpose: 14-3-3η is an emerging soluble Rheumatoid Arthritis (RA) biomarker that activates intracellular pathways that lead to the upregulation of inflammatory and joint damage factors.…
  • Abstract Number: 185 • 2015 ACR/ARHP Annual Meeting

    Success Rate and Utility of Ultrasound Guided Synovial Biopsies in Clinical Practice

    Aurélie Najm, Benoît Le Goff and Yves Maugars, Rheumatology, Rheumatology, Nantes, France

    Background/Purpose: Histological and bacteriological analysis of synovial tissue (ST) can be useful in the diagnosis of arthritis of undetermined origin. Ultrasound can assist this biopsy…
  • Abstract Number: 2587 • 2015 ACR/ARHP Annual Meeting

    CRP and 14-3-3η Are Each Associated with Joint Damage Progression, Their Titres Do Not Correlate and Are Better Predictors of Progression Together Than Alone

    Gilles Boire1,2, Nathalie Carrier3, Artur de Brum-Fernandes1,4, Patrick Liang1,4, Ariel Masetto2,5, Yuan Gui6, Jane Savill6, Sara Michienzi6, Henri Ménard7, Walter Maksymowych8 and Anthony Marotta6, 1Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 2Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, 3Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 5Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 6Augurex Life Sciences Corp., Vancouver, BC, Canada, 7MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, 8Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: As a marker of inflammation and an acute phase reactant, C-reactive protein (CRP) is routinely used in clinical practice and in RA classification criteria.…
  • Abstract Number: 240 • 2015 ACR/ARHP Annual Meeting

    Volumetric Assessment of Tophaceous Gout

    Ralf G. Thiele1, Laura Coates2 and Darren Tabechian1, 1University of Rochester Medical Center, Rochester, NY, 2Medicine, University of Rochester, Rochester, NY

    Background/Purpose: Ultrasound (US) can identify monosodium urate (MSU) tophi within joints, tendons, bursae and other soft tissues. The ability to readily, quickly and inexpensively assess…
  • Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting

    Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients

    Nathalie Carrier1, Anthony Marotta2, Artur de Brum-Fernandes3,4, Patrick Liang3,4, Ariel Masetto5,6, Yuan Gui2, Jane Savill2, Sara Michienzi2, Henri Ménard7, Walter Maksymowych8 and Gilles Boire4, 1Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 2Augurex Life Sciences Corp., Vancouver, BC, Canada, 3Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 5Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 6Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, 7MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, 8Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…
  • Abstract Number: 509 • 2015 ACR/ARHP Annual Meeting

    In Early Undifferentiated Polyarthritis, 14-3-3η Seroreversion or Sustained Negativity Is Associated with Better Radiographic Outcomes, Even in DAS-28 Remitters

    Gilles Boire1,2, Nathalie Carrier3, Artur de Brum-Fernandes1,4, Patrick Liang1,4, Ariel Masetto2,5, Yuan Gui6, Jane Savill6, Sara Michienzi6, Henri Ménard7, Walter Maksymowych8 and Anthony Marotta6, 1Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 2Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, 3Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 4Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, 5Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, 6Augurex Life Sciences Corp., Vancouver, BC, Canada, 7MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, 8Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Advancements in RA treatment approaches with DMARDs and biological agents have enabled disease remission goals that were previously considered unattainable. The concept of "tight…
  • Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting

    Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus

    Tianfu Wu1, Huihua Ding2, Cristina Arriens3, Chungwen Wei4, Jennifer H. Anolik5, David R. Karp3, Nancy J. Olsen6, Michelle Petri7, Ignacio Sanz4, Ramesh Saxena8 and Chandra Mohan2, 1Department of Biomedical Engineering, University of Houston, Houston, TX, 2Biomedical Engineering, University of Houston, Houston, TX, 3Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, 4Rheumatology, Emory University, Atlanta, GA, 5University of Rochester Medical Center, Rochester, NY, 6Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, 7Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, 8Nephrology, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
  • Abstract Number: 621 • 2015 ACR/ARHP Annual Meeting

    Previous Diagnosis of Sjögren’s Syndrome As Rheumatoid Arthritis or Systemic Lupus Erythematosus

    Astrid Rasmussen1, Lida Radfar2, Kiely Grundahl3, David M. Lewis4, Donald U Stone5,6, C. Erick Kaufman7, Daniel J Wallace8, Michael H. Weisman9, Swamy Venuturupalli10, Christopher J Lessard11, Biji Kurien12, Juan-Manuel Anaya13, Michael D. Rohrer14, Raj Gopalakrishnan15, Glen D Houston16, James Chodosh17, Pamela J Hughes18, Nelson L. Rhodus19, John Ice1, Kimberly Hefner20, Jennifer A. Kelly21, Kathy L. Sivils1 and R. Hal Scofield1,22,23, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 4College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, 6Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, 7College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10Cedars-Sinai Medical Center, West Hollywood, CA, 11Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 14Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, 15Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, 16Heartland Pathology, Oklahoma City, OK, 17Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, 18Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, 19Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, 20Hefner Eye Care and Optical Center, Oklahoma City, OK, 21Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 22Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 23US Department of Veterans Affairs Medical Center, Oklahoma City, OK

    Background/Purpose: The diagnosis of Sjögren′s Syndrome (SS) is often difficult and many patients are symptomatic for years with other diagnoses before confirmation of SS. Overlapping…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology